Amir T. Fathi

571 total citations
24 papers, 233 citations indexed

About

Amir T. Fathi is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Amir T. Fathi has authored 24 papers receiving a total of 233 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 10 papers in Molecular Biology and 5 papers in Genetics. Recurrent topics in Amir T. Fathi's work include Acute Myeloid Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Histone Deacetylase Inhibitors Research (5 papers). Amir T. Fathi is often cited by papers focused on Acute Myeloid Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Histone Deacetylase Inhibitors Research (5 papers). Amir T. Fathi collaborates with scholars based in United States, South Korea and France. Amir T. Fathi's co-authors include Andrew M. Brunner, Donna Neuberg, Hossein Sadrzadeh, Traci M. Blonquist, Philip C. Amrein, Yi‐Bin Chen, Benjamin J. Drapkin, Federico Campigotto, Karen K. Ballen and Ashley Perry and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Amir T. Fathi

21 papers receiving 226 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amir T. Fathi United States	7	175	95	73	32	22	24	233
Michelina Santopietro Italy	9	178 1.0×	155 1.6×	15 0.2×	23 0.7×	22 1.0×	37	234
Sophie Dobbelstein France	6	168 1.0×	80 0.8×	101 1.4×	68 2.1×	5 0.2×	7	261
Maria López‐Pavía Spain	9	108 0.6×	31 0.3×	102 1.4×	21 0.7×	9 0.4×	21	183
Alexander Sternberg United Kingdom	7	203 1.2×	107 1.1×	68 0.9×	38 1.2×	56 2.5×	14	278
Galina Tsykunova Norway	8	147 0.8×	25 0.3×	103 1.4×	30 0.9×	21 1.0×	25	200
José Antonio Queizán Spain	7	103 0.6×	48 0.5×	74 1.0×	58 1.8×	18 0.8×	13	169
Daniella Kerbauy United States	4	226 1.3×	147 1.5×	89 1.2×	21 0.7×	32 1.5×	7	277
Chin Yang Li United States	7	148 0.8×	188 2.0×	99 1.4×	33 1.0×	80 3.6×	13	306
Fernando Roncolato Australia	8	109 0.6×	48 0.5×	57 0.8×	39 1.2×	14 0.6×	17	183
Yasufumi Kawasaki Japan	9	93 0.5×	36 0.4×	34 0.5×	33 1.0×	38 1.7×	19	173

Countries citing papers authored by Amir T. Fathi

Since Specialization

Citations

This map shows the geographic impact of Amir T. Fathi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amir T. Fathi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amir T. Fathi more than expected).

Fields of papers citing papers by Amir T. Fathi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amir T. Fathi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amir T. Fathi. The network helps show where Amir T. Fathi may publish in the future.

Co-authorship network of co-authors of Amir T. Fathi

This figure shows the co-authorship network connecting the top 25 collaborators of Amir T. Fathi. A scholar is included among the top collaborators of Amir T. Fathi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amir T. Fathi. Amir T. Fathi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Malki, Monzr M. Al, Elizabeth Rich, Jason E. Hill, et al.. (2025). Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study. Leukemia Research. 152. 107690–107690. 2 indexed citations

Aubrey, Brandon J., Traci M. Blonquist, Malgorzata McMasters, et al.. (2025). A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. Leukemia Research. 153. 107693–107693. 1 indexed citations

Gutierrez, Catherine, Anthony S. Stein, Amir T. Fathi, & Vinod Pullarkat. (2025). Treatment of Relapsed/Refractory AML—Novel Treatment Options Including Immunotherapy. American Journal of Hematology. 100(S2). 23–37. 6 indexed citations

Pullarkat, Vinod, Mark J. Levis, James A. McCloskey, et al.. (2025). V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML. PubMed. 2(4). 100123–100123. 1 indexed citations

Azarboo, Alireza, et al.. (2025). Secondary mutational and cytogenetic alterations in core binding factor – Acute myeloid leukemia (CBF-AML): A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 212. 104770–104770.

Montesinos, Pau, June‐Won Cheong, Naval Daver, et al.. (2025). QuANTUM-Wild: A phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in FLT3 -ITD–negative acute myeloid leukemia (AML).. Journal of Clinical Oncology. 43(16_suppl).

El‐Jawahri, Areej, Joseph A. Greer, Vicki A. Jackson, et al.. (2024). Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy.. Journal of Clinical Oncology. 42(17_suppl). LBA6508–LBA6508.

Brunner, Andrew M., Yiwen Liu, Rupa Narayan, et al.. (2024). Safety and Activity of the TIM3 Inhibitor Sabatolimab in Patients with Lower-Risk Myelodysplastic Syndromes. Blood. 144(Supplement 1). 6726–6726. 1 indexed citations

Dhawale, Tejaswini, Valentina Nardi, Charlotte Wang, et al.. (2024). Impact of Ultra Rapid Molecular Profiling on Treatment Delays and Healthcare Utilization of Patients Hospitalized for Acute Leukemia. Blood. 144(Supplement 1). 5058–5058. 1 indexed citations

10.

Brunner, Andrew M., Yiwen Liu, Jacqueline S. Garcia, et al.. (2024). Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy. Blood. 144(Supplement 1). 1833–1833. 1 indexed citations

11.

Fathi, Amir T., Geoffrey Fell, Areej El‐Jawahri, et al.. (2022). A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia. Blood. 140(Supplement 1). 3284–3286. 2 indexed citations

12.

Brunner, Andrew M., Yiwen Liu, Lourdes Mendez, et al.. (2021). Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study. Blood. 138(Supplement 1). 1521–1521. 6 indexed citations

13.

Fathi, Amir T., et al.. (2021). Utilization of Internal Bracing in Elbow Medial UCL Stabilization: From Biomechanics to Clinical Application and Patient Outcomes. Orthopedic Research and Reviews. Volume 13. 201–208. 4 indexed citations

14.

Brunner, Andrew M., Traci M. Blonquist, Gabriela Hobbs, et al.. (2017). Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Advances. 1(23). 2032–2040. 35 indexed citations

15.

Kovach, Alexandra E., Andrew M. Brunner, Amir T. Fathi, Yi‐Bin Chen, & Robert P. Hasserjian. (2016). Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation. American Journal of Clinical Pathology. 147(1). aqw203–aqw203. 2 indexed citations

16.

Brunner, Andrew M., Traci M. Blonquist, Hossein Sadrzadeh, et al.. (2014). Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis. Leukemia & lymphoma. 56(6). 1698–1703. 57 indexed citations

17.

Brunner, Andrew M., Traci M. Blonquist, Ashmeet Bhatia, et al.. (2014). Outcomes among patients with isolated myeloid sarcoma: A SEER database analysis.. Journal of Clinical Oncology. 32(15_suppl). 7075–7075. 1 indexed citations

18.

Brunner, Andrew M., Traci M. Blonquist, Hossein Sadrzadeh, et al.. (2013). Trends In Outcomes In Core Binding Factor Acute Myeloid Leukemia: A SEER Database Analysis. Blood. 122(21). 3880–3880. 1 indexed citations

19.

Brunner, Andrew M., Federico Campigotto, Hossein Sadrzadeh, et al.. (2013). Trends in all‐cause mortality among patients with chronic myeloid leukemia. Cancer. 119(14). 2620–2629. 55 indexed citations

20.

Zhang, Yiyun, Jianfeng Wang, Justin C. Wheat, et al.. (2013). AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway. Blood. 121(24). 4906–4916. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact